Novartis has axed two late-stage programs in cancer-related blood clots after observing “inferior efficacy” in a clinical trial.
The move marks a setback for a candidate that Novartis out-licensed in 2019, then
Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.
A scheme to hasten the diagnosis of children with genetic disorders is achieving strong results and could be a template for national health systems.
Over the weekend, President Donald Trump endorsed the potential of psychedelic treatments and vowed to expedite their research and development as remedies for severe mental
Merck partner reveals first human data for PD-1xVEGF bispecific: Sino Biopharm revealed that six of 11 lung cancer patients responded to a low dose of
The investor Venrock will make $900 million on a relatively small $20 million investment into Kelonia Therapeutics, which on Monday agreed to sell itself to
Novartis has axed two late-stage programs in cancer-related blood clots after observing “inferior efficacy” in a clinical trial.
The move marks a setback for a candidate that Novartis out-licensed in 2019, then